(HealthDay)—For patients with multiple myeloma in whom treatment with lenalidomide and a proteasome inhibitor has failed, progression-free survival (PFS) is longer in those receiving the immunostimulatory monoclonal antibody ...
Nov 8, 2018
0
0
Scientists have found a way to boost the efficacy of the world's most powerful antimalarial drug with the help of chemotherapy medicines, according to new research published in the journal Nature Communications.
Sep 20, 2018
0
44
The proteasome inhibitor carfilzomib has taken on an increasing role in the treatment of multiple myeloma, but new research from the Abramson Cancer Center of the University of Pennsylvania shows the therapy comes with the ...
Dec 28, 2017
0
6
A new class of drugs for blood cancers such as leukemia and multiple myeloma is showing promise. But it is hobbled by a problem that also plagues other cancer drugs: targeted cells can develop resistance. Now scientists, ...
Oct 25, 2017
0
1
Some of the most promising new treatments for blood cancers, drugs called proteasome inhibitors, have a problem: For reasons that researchers are still working to fully understand, cancer cells can build up a resistance to ...
Oct 25, 2017
0
0
The use of proteasome inhibitors to treat cancer has been greatly limited by the ability of cancer cells to develop resistance to these drugs. But Whitehead Institute researchers have found a mechanism underlying this resistance—a ...
Dec 27, 2016
0
61
An experimental drug that blocks the activation of an immune cell component effectively prevented rejection of heart transplants in mice, according to new research from scientists at Weill Cornell Medicine and Brigham and ...
Dec 13, 2016
0
113
Maintaining appropriate levels of proteins within cells largely relies on a cellular component called the proteasome, which degrades unneeded or defective proteins to recycle the components for the eventual assembly of new ...
Aug 16, 2016
0
194
Moffitt Cancer Center will present results from a phase 1 study of selinexor in combination with liposomal doxorubicin and dexamethasone in patients with relapsed and refractory multiple myeloma. The findings will be discussed ...
Jun 6, 2016
0
30
De Bruin carries out chemical-biological research on proteasomes. 'They are a kind of degradation factory that cuts proteins in cells into smaller fragments. It's a highly useful activity: it's a way for cells to clean up ...
May 31, 2016
0
5
